Yusuke Nishimura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yusuke Nishimura has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Akihito Hiromori
The University of Osaka, Suita, Japan
1 shared publication Akira Suwa
Research & Sumitomo Electric Industries, LTD., Osaka, Japan
1 shared publication- Atsushi Fujita
Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan
1 shared publication Han-Hsiu Hsu
Division of Bioindustrial Sciences, Graduate School of Life and Environmental Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba City, Ibaraki 305-8572, Japan
1 shared publicationHirofumi Urayama
Research & Sumitomo Electric Industries, LTD., Osaka, Japan
1 shared publication- Hiroyuki Nakajima
Department of Cell Biology, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan
1 shared publication
Latest Publications
- 27 August 2026
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 49 (12) , 839-848
Toward a conceptual framework for systemic effects of continuous renal replacement therapy in critical illness
Continuous renal replacement therapy (CRRT) is traditionally used for solute and fluid removal in critically ill patients with acute kidney injury. Emerging evidence suggests that CRRT may also influence systemic biological networks, including inflammation, vascular function, immunity, and metabolism. In sepsis and critical illness, these systems are dynamically dysregulated, involving fluctuating inflammatory mediators, endothelial alterations, immune dysfunction ranging from hyperinflammation to immunoparalysis, and metabolic reprogramming that varies with disease stage. We propose a conceptual framework in which CRRT modulates these interconnected processes. Beyond solute and cytokine removal, CRRT may affect the distribution of circulating mediators, attenuate concentration peaks, influence endothelial stability, and modulate immune and metabolic states, thereby contributing to systemic network regulation. However, CRRT has bidirectional effects. While it may help restore homeostasis by removing harmful mediators, it may also eliminate beneficial molecules and induce inflammatory or oxidative responses due to extracorporeal circulation. Therefore, its overall impact is likely context-dependent and influenced by treatment settings and patient condition. Although direct evidence for systemic reprogramming remains limited, this framework provides a basis for future research. Integrative biomarker-based and phenotyping approaches may support the development of individualized and adaptive CRRT strategies in critical care.
- 27 August 2026
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 49 (12) , 839-848
Toward a conceptual framework for systemic effects of continuous renal replacement therapy in critical illness
Continuous renal replacement therapy (CRRT) is traditionally used for solute and fluid removal in critically ill patients with acute kidney injury. Emerging evidence suggests that CRRT may also influence systemic biological networks, including inflammation, vascular function, immunity, and metabolism. In sepsis and critical illness, these systems are dynamically dysregulated, involving fluctuating inflammatory mediators, endothelial alterations, immune dysfunction ranging from hyperinflammation to immunoparalysis, and metabolic reprogramming that varies with disease stage. We propose a conceptual framework in which CRRT modulates these interconnected processes. Beyond solute and cytokine removal, CRRT may affect the distribution of circulating mediators, attenuate concentration peaks, influence endothelial stability, and modulate immune and metabolic states, thereby contributing to systemic network regulation. However, CRRT has bidirectional effects. While it may help restore homeostasis by removing harmful mediators, it may also eliminate beneficial molecules and induce inflammatory or oxidative responses due to extracorporeal circulation. Therefore, its overall impact is likely context-dependent and influenced by treatment settings and patient condition. Although direct evidence for systemic reprogramming remains limited, this framework provides a basis for future research. Integrative biomarker-based and phenotyping approaches may support the development of individualized and adaptive CRRT strategies in critical care.
- 8 August 2026
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 44 (9)
Function-first organoid engineering for regenerative medicine: current challenges and future perspectives
Organoid technology has emerged as a powerful platform for modeling human development, disease, and drug responses. Advances in stem cell biology and bioengineering have enabled the generation of increasingly sophisticated organoid systems that recapitulate key structural and cellular features of native tissues. However, despite substantial progress, the translational impact of organoids in regenerative medicine remains limited. Greater structural complexity and anatomical resemblance have not consistently translated into sustained therapeutic function or clinical applicability. Major barriers include incomplete maturation, inadequate vascular and immune integration, limited long-term functional stability, and challenges in reproducibility and scalability. These limitations reflect a conceptual mismatch between structure-driven organoid development and the functional requirements of regenerative medicine. Here, we propose a function-first framework in which regenerative organoids are engineered and evaluated according to measurable therapeutic outcomes, including tissue-specific function, vascular integration, immune compatibility, reproducibility, scalability, and long-term stability. We further discuss emerging bioengineering strategies, including vascularization, immune incorporation, organ-on-a-chip platforms, advanced biomaterials, and automated manufacturing, that may accelerate clinical translation. Reframing organoids as functionally engineered therapeutic platforms rather than increasingly complex anatomical models provides a conceptual foundation for advancing regenerative organoid therapies.
- 8 August 2026
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 44 (9)
Function-first organoid engineering for regenerative medicine: current challenges and future perspectives
Organoid technology has emerged as a powerful platform for modeling human development, disease, and drug responses. Advances in stem cell biology and bioengineering have enabled the generation of increasingly sophisticated organoid systems that recapitulate key structural and cellular features of native tissues. However, despite substantial progress, the translational impact of organoids in regenerative medicine remains limited. Greater structural complexity and anatomical resemblance have not consistently translated into sustained therapeutic function or clinical applicability. Major barriers include incomplete maturation, inadequate vascular and immune integration, limited long-term functional stability, and challenges in reproducibility and scalability. These limitations reflect a conceptual mismatch between structure-driven organoid development and the functional requirements of regenerative medicine. Here, we propose a function-first framework in which regenerative organoids are engineered and evaluated according to measurable therapeutic outcomes, including tissue-specific function, vascular integration, immune compatibility, reproducibility, scalability, and long-term stability. We further discuss emerging bioengineering strategies, including vascularization, immune incorporation, organ-on-a-chip platforms, advanced biomaterials, and automated manufacturing, that may accelerate clinical translation. Reframing organoids as functionally engineered therapeutic platforms rather than increasingly complex anatomical models provides a conceptual foundation for advancing regenerative organoid therapies.
- 5 July 2026
- Published by Springer Nature in Human Cell
- Vol. 39 (7)
Vascular reprogramming in cancer: engineering the tumor microenvironment
Tumor vasculature has traditionally been viewed as structurally and functionally abnormal and, therefore, is primarily targeted for inhibition. However, emerging evidence from vascular biology, regenerative medicine, and bioengineering challenges this paradigm, demonstrating that blood vessels actively instruct and shape the tumor microenvironment. Here, we propose that tumor vasculature functions as a dynamic and programmable interface that regulates cancer progression and define vascular reprogramming as a therapeutic strategy to actively redesign vascular structure, function, and signaling to control the tumor ecosystem. By integrating recent advances in endothelial cell heterogeneity, vascular niche biology, and multiscale modeling, we illustrate how tumor vessels govern cancer stemness, immune-cell trafficking, and metabolic adaptation, positioning the vasculature as a central regulatory hub rather than a passive conduit. We further highlight enabling technologies, including vascularized organoids, organ-on-a-chip systems, and iPSC-derived vasculature, that enable the precise reconstruction and manipulation of human vascular microenvironments, providing unprecedented opportunities to experimentally control vascular dynamics. Importantly, we distinguish vascular reprogramming from conventional anti-angiogenic and normalization strategies, emphasizing its potential to achieve sustained and integrative control of the tumor microenvironment. By modulating vascular permeability, perfusion, and immunoregulatory signaling, this approach enhances drug delivery, improves immune infiltration, and increases therapeutic sensitivity. Finally, we discuss the key challenges for clinical translation, including safety, scalability, and model limitations, and highlight future directions driven by spatial omics and artificial intelligence. Collectively, this framework establishes tumor vasculature as a designable therapeutic interface and advances a new paradigm in cancer therapy: not merely targeting the tumor microenvironment but engineering it through vascular control.
- 5 July 2026
- Published by Springer Nature in Human Cell
- Vol. 39 (7)
Vascular reprogramming in cancer: engineering the tumor microenvironment
Tumor vasculature has traditionally been viewed as structurally and functionally abnormal and, therefore, is primarily targeted for inhibition. However, emerging evidence from vascular biology, regenerative medicine, and bioengineering challenges this paradigm, demonstrating that blood vessels actively instruct and shape the tumor microenvironment. Here, we propose that tumor vasculature functions as a dynamic and programmable interface that regulates cancer progression and define vascular reprogramming as a therapeutic strategy to actively redesign vascular structure, function, and signaling to control the tumor ecosystem. By integrating recent advances in endothelial cell heterogeneity, vascular niche biology, and multiscale modeling, we illustrate how tumor vessels govern cancer stemness, immune-cell trafficking, and metabolic adaptation, positioning the vasculature as a central regulatory hub rather than a passive conduit. We further highlight enabling technologies, including vascularized organoids, organ-on-a-chip systems, and iPSC-derived vasculature, that enable the precise reconstruction and manipulation of human vascular microenvironments, providing unprecedented opportunities to experimentally control vascular dynamics. Importantly, we distinguish vascular reprogramming from conventional anti-angiogenic and normalization strategies, emphasizing its potential to achieve sustained and integrative control of the tumor microenvironment. By modulating vascular permeability, perfusion, and immunoregulatory signaling, this approach enhances drug delivery, improves immune infiltration, and increases therapeutic sensitivity. Finally, we discuss the key challenges for clinical translation, including safety, scalability, and model limitations, and highlight future directions driven by spatial omics and artificial intelligence. Collectively, this framework establishes tumor vasculature as a designable therapeutic interface and advances a new paradigm in cancer therapy: not merely targeting the tumor microenvironment but engineering it through vascular control.
- 22 June 2026
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 29 (3) , 37
Engineering brain organoids: from neurodevelopmental modeling to translational barriers
Brain organoids have progressed from simple three-dimensional neuroepithelial aggregates to increasingly sophisticated systems that recapitulate key aspects of human neurodevelopment and disease. Despite rapid biological advances, their translational potential remains constrained by challenges in maturation, vascular integration, reproducibility, and scalable standardization. Recent innovations, including microfluidic perfusion platforms, synthetic extracellular matrices, vascularization strategies, and modular assembloid assembly, illustrate a shift from descriptive modeling to functionally integrated and experimentally controllable neural systems. However, increasing biological complexity introduces ethical and regulatory considerations that must be incorporated into translational research frameworks. These advances provide new opportunities to investigate human-specific developmental mechanisms and bridge the gap between in vitro modeling and in vivo neurobiology. Future progress will depend on balancing two complementary objectives: enhancing biological fidelity and improving experimental utility through increasingly controllable and design-driven organoid platforms with defined architecture, functionality, and reproducibility. In this context, brain organoids are emerging as bioengineered neural tissue systems that share important conceptual and technological foundations with next-generation artificial organ technologies. Continued advances in bioengineering, standardization, and systems-level integration are essential to maximize their translational impact on disease modeling, therapeutic testing, and regenerative neuroscience.
- 22 June 2026
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 29 (3) , 37
Engineering brain organoids: from neurodevelopmental modeling to translational barriers
Brain organoids have progressed from simple three-dimensional neuroepithelial aggregates to increasingly sophisticated systems that recapitulate key aspects of human neurodevelopment and disease. Despite rapid biological advances, their translational potential remains constrained by challenges in maturation, vascular integration, reproducibility, and scalable standardization. Recent innovations, including microfluidic perfusion platforms, synthetic extracellular matrices, vascularization strategies, and modular assembloid assembly, illustrate a shift from descriptive modeling to functionally integrated and experimentally controllable neural systems. However, increasing biological complexity introduces ethical and regulatory considerations that must be incorporated into translational research frameworks. These advances provide new opportunities to investigate human-specific developmental mechanisms and bridge the gap between in vitro modeling and in vivo neurobiology. Future progress will depend on balancing two complementary objectives: enhancing biological fidelity and improving experimental utility through increasingly controllable and design-driven organoid platforms with defined architecture, functionality, and reproducibility. In this context, brain organoids are emerging as bioengineered neural tissue systems that share important conceptual and technological foundations with next-generation artificial organ technologies. Continued advances in bioengineering, standardization, and systems-level integration are essential to maximize their translational impact on disease modeling, therapeutic testing, and regenerative neuroscience.
- 5 February 2026
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 29 (1) , 18
Vascularization and maturation of kidney organoids: a comprehensive review of technological trends and challenges
Chronic kidney disease is a global health issue, and novel therapeutic alternatives to dialysis and kidney transplantation must be developed. Human-induced pluripotent stem cell-derived kidney organoids recapitulate developmental processes and mimic kidney-like structures in vitro and have thus attracted attention for treating chronic kidney disease. However, the limited vascularization and immaturity of human-induced pluripotent stem cell-derived kidney organoids remain major barriers to their clinical application. The latest technological advances and specific challenges in kidney organoid vascularization and maturation were thoroughly examined in this review. Diverse approaches were considered, including coculturing with endothelial cells, in vivo transplantation, applying biomaterials and microfluidic systems, controlling molecular signaling, and metabolic reprogramming. However, issues persist such as low reproducibility, lack of standardization, insufficient functional evaluations, and inadequate safety assessments. Future studies should focus on developing multifactorial and strategies for integrating multiple cell types, establishing maturation assessment criteria, and verifying the long-term functionality and safety of three-dimensional bioprinting technologies. Technologies for the vascularization and maturation of kidney organoids show promise as foundational methods for use innovative regenerative medicine and the development of drug discovery therapies.
- 5 February 2026
- Published by Springer Nature in Journal of Artificial Organs
- Vol. 29 (1) , 18
Vascularization and maturation of kidney organoids: a comprehensive review of technological trends and challenges
Chronic kidney disease is a global health issue, and novel therapeutic alternatives to dialysis and kidney transplantation must be developed. Human-induced pluripotent stem cell-derived kidney organoids recapitulate developmental processes and mimic kidney-like structures in vitro and have thus attracted attention for treating chronic kidney disease. However, the limited vascularization and immaturity of human-induced pluripotent stem cell-derived kidney organoids remain major barriers to their clinical application. The latest technological advances and specific challenges in kidney organoid vascularization and maturation were thoroughly examined in this review. Diverse approaches were considered, including coculturing with endothelial cells, in vivo transplantation, applying biomaterials and microfluidic systems, controlling molecular signaling, and metabolic reprogramming. However, issues persist such as low reproducibility, lack of standardization, insufficient functional evaluations, and inadequate safety assessments. Future studies should focus on developing multifactorial and strategies for integrating multiple cell types, establishing maturation assessment criteria, and verifying the long-term functionality and safety of three-dimensional bioprinting technologies. Technologies for the vascularization and maturation of kidney organoids show promise as foundational methods for use innovative regenerative medicine and the development of drug discovery therapies.
- 12 January 2026
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 44 (4)
Stem cell and bioengineering approaches for end-stage renal disease: a comprehensive review
End-stage renal disease (ESRD) is a major global health burden, and current treatments, such as dialysis and kidney transplantation, remain constrained by donor shortages, procedure-related complications, and reduced long-term quality of life. Regenerative medicine, particularly stem cell-based approaches, offers promising next-generation strategies for kidney repair and replacement. This review summarizes the current understanding of kidney development and intrinsic regenerative capacity and evaluates the therapeutic potential of hematopoietic stem cells, mesenchymal stem cells (MSCs), kidney-derived stem cells, and induced pluripotent stem cell (iPSC)-derived kidney organoids. Evidence from preclinical models demonstrates renoprotective and immunomodulatory effects across multiple stem cell types, whereas early-phase clinical trials have reported favorable safety profiles and preliminary signals of the efficacy of MSC-based therapies. iPSC- and organoid-based approaches present additional challenges, including incomplete vascularization, immature nephron structures, risks of tumorigenicity, immune compatibility issues, and the need for reproducible good manufacturing practice (GMP)-compliant manufacturing. Advances in biomaterials, organoid engineering, and vascularization strategies may help overcome these barriers. Overall, stem cell-based regenerative therapies show substantial potential to complement or ultimately reduce the reliance on dialysis and transplantation. Continued technological innovations and rigorously designed clinical trials are critical to translate these promising approaches into clinical practice.
- 12 January 2026
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 44 (4)
Stem cell and bioengineering approaches for end-stage renal disease: a comprehensive review
End-stage renal disease (ESRD) is a major global health burden, and current treatments, such as dialysis and kidney transplantation, remain constrained by donor shortages, procedure-related complications, and reduced long-term quality of life. Regenerative medicine, particularly stem cell-based approaches, offers promising next-generation strategies for kidney repair and replacement. This review summarizes the current understanding of kidney development and intrinsic regenerative capacity and evaluates the therapeutic potential of hematopoietic stem cells, mesenchymal stem cells (MSCs), kidney-derived stem cells, and induced pluripotent stem cell (iPSC)-derived kidney organoids. Evidence from preclinical models demonstrates renoprotective and immunomodulatory effects across multiple stem cell types, whereas early-phase clinical trials have reported favorable safety profiles and preliminary signals of the efficacy of MSC-based therapies. iPSC- and organoid-based approaches present additional challenges, including incomplete vascularization, immature nephron structures, risks of tumorigenicity, immune compatibility issues, and the need for reproducible good manufacturing practice (GMP)-compliant manufacturing. Advances in biomaterials, organoid engineering, and vascularization strategies may help overcome these barriers. Overall, stem cell-based regenerative therapies show substantial potential to complement or ultimately reduce the reliance on dialysis and transplantation. Continued technological innovations and rigorously designed clinical trials are critical to translate these promising approaches into clinical practice.
- 2 October 2025
- Published by Springer Nature in Human Cell
- Vol. 38 (6) , 1-10
Podocytes in health and disease: from development to regeneration
Podocytes are highly specialized epithelial cells that are essential for maintaining the glomerular filtration barrier. They originate from the metanephric mesenchyme during kidney development, with differentiation tightly regulated by transcription factors, such as Wt1, MafB, and Lmx1b, as well as signaling pathways, including Wnt and Notch. Mature podocytes form intricate foot processes and slit diaphragms, coordinating membrane proteins, such as nephrin and podocin, with the actin cytoskeleton to ensure selective filtration. Owing to their limited regenerative capacity, podocyte injury caused by genetic mutations, mechanical stress, metabolic disorders, or inflammation leads to proteinuria, glomerulosclerosis, and the progression of chronic kidney disease. Recent studies have elucidated diverse injury mechanisms, including apoptosis, necroptosis, ferroptosis, and cytoskeletal dysregulation, highlighting aging and lipid metabolism as key modulators of podocyte vulnerability. Advances in stem cell technology and kidney organoids have enabled the modeling of podocyte development and disease, paving the way for regenerative strategies. This review provides a comprehensive overview of podocyte biology, injury mechanisms, and emerging therapeutic approaches, emphasizing translational opportunities for protecting and restoring podocyte function in kidney diseases.
- 2 October 2025
- Published by Springer Nature in Human Cell
- Vol. 38 (6) , 1-10
Podocytes in health and disease: from development to regeneration
Podocytes are highly specialized epithelial cells that are essential for maintaining the glomerular filtration barrier. They originate from the metanephric mesenchyme during kidney development, with differentiation tightly regulated by transcription factors, such as Wt1, MafB, and Lmx1b, as well as signaling pathways, including Wnt and Notch. Mature podocytes form intricate foot processes and slit diaphragms, coordinating membrane proteins, such as nephrin and podocin, with the actin cytoskeleton to ensure selective filtration. Owing to their limited regenerative capacity, podocyte injury caused by genetic mutations, mechanical stress, metabolic disorders, or inflammation leads to proteinuria, glomerulosclerosis, and the progression of chronic kidney disease. Recent studies have elucidated diverse injury mechanisms, including apoptosis, necroptosis, ferroptosis, and cytoskeletal dysregulation, highlighting aging and lipid metabolism as key modulators of podocyte vulnerability. Advances in stem cell technology and kidney organoids have enabled the modeling of podocyte development and disease, paving the way for regenerative strategies. This review provides a comprehensive overview of podocyte biology, injury mechanisms, and emerging therapeutic approaches, emphasizing translational opportunities for protecting and restoring podocyte function in kidney diseases.
- 5 September 2025
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 48 (9) , 627-635
Innovations in cardiac regenerative medicine: The role of tissue engineering
Cardiovascular disease (CVD) is a leading cause of death worldwide. CVD includes conditions such as myocardial infarction (MI), arrhythmias, valvular heart disease, and cardiomyopathy. The limitations of heart treatment are related to the inability of damaged cells to regenerate, which leads to an increasing demand for new therapies. Cardiac tissue engineering (CTE) aims to efficiently regenerate damaged cardiac tissues by combining cells and biomaterials to address these diseases. Various cell types have been used in CTE research, including adult and pluripotent stem cells, the latter differentiating into functional cardiomyocytes. An ideal biomaterial promotes efficient adhesion, growth, and differentiation of cardiac cells and possesses the appropriate characteristics needed for functional cardiac cells, showing great potential for heart repair and regeneration. This review focuses on various tissue engineering approaches for the regeneration and repair of cardiac tissues following myocardial infarction.
- 5 September 2025
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 48 (9) , 627-635
Innovations in cardiac regenerative medicine: The role of tissue engineering
Cardiovascular disease (CVD) is a leading cause of death worldwide. CVD includes conditions such as myocardial infarction (MI), arrhythmias, valvular heart disease, and cardiomyopathy. The limitations of heart treatment are related to the inability of damaged cells to regenerate, which leads to an increasing demand for new therapies. Cardiac tissue engineering (CTE) aims to efficiently regenerate damaged cardiac tissues by combining cells and biomaterials to address these diseases. Various cell types have been used in CTE research, including adult and pluripotent stem cells, the latter differentiating into functional cardiomyocytes. An ideal biomaterial promotes efficient adhesion, growth, and differentiation of cardiac cells and possesses the appropriate characteristics needed for functional cardiac cells, showing great potential for heart repair and regeneration. This review focuses on various tissue engineering approaches for the regeneration and repair of cardiac tissues following myocardial infarction.
- Open Access
- 8 August 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (11) , 1718-1726
Origins and Molecular Mechanisms Underlying Renal Vascular Development
Kidneys play a crucial role in maintaining homeostasis within the body, and this function is intricately linked to the vascular structures within them. For vascular cells in the kidney to mature and function effectively, a well-coordinated spatial alignment between the nephrons and complex network of blood vessels is essential. This arrangement ensures efficient blood filtration and regulation of the electrolyte balance, blood pressure, and fluid levels. Additionally, the kidneys are vital in regulating the acid-base balance and producing hormones involved in erythropoiesis and blood pressure control. This article focuses on the vascular development of the kidneys, summarizing the current understanding of the origin and formation of the renal vasculature, and the key molecules involved. A comprehensive review of existing studies has been conducted to elucidate the cellular and molecular mechanisms governing renal vascular development. Specific molecules play a critical role in the development of renal vasculature, contributing to the spatial alignment between nephrons and blood vessels. By elucidating the cellular and molecular mechanisms involved in renal vascular development, this study aims to advance renal regenerative medicine and offer potential avenues for therapeutic interventions in kidney disease.
- 8 August 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (11) , 1718-1726
Open AccessOrigins and Molecular Mechanisms Underlying Renal Vascular Development
Kidneys play a crucial role in maintaining homeostasis within the body, and this function is intricately linked to the vascular structures within them. For vascular cells in the kidney to mature and function effectively, a well-coordinated spatial alignment between the nephrons and complex network of blood vessels is essential. This arrangement ensures efficient blood filtration and regulation of the electrolyte balance, blood pressure, and fluid levels. Additionally, the kidneys are vital in regulating the acid-base balance and producing hormones involved in erythropoiesis and blood pressure control. This article focuses on the vascular development of the kidneys, summarizing the current understanding of the origin and formation of the renal vasculature, and the key molecules involved. A comprehensive review of existing studies has been conducted to elucidate the cellular and molecular mechanisms governing renal vascular development. Specific molecules play a critical role in the development of renal vasculature, contributing to the spatial alignment between nephrons and blood vessels. By elucidating the cellular and molecular mechanisms involved in renal vascular development, this study aims to advance renal regenerative medicine and offer potential avenues for therapeutic interventions in kidney disease.
- Open Access
- 17 June 2024
- Published by Elsevier in Regenerative Therapy
- Vol. 26, 275-280
Revolutionizing renal research: The future of kidney-on-a-chip in biotechnology
- 17 June 2024
- Published by Elsevier in Regenerative Therapy
- Vol. 26, 275-280
Open AccessRevolutionizing renal research: The future of kidney-on-a-chip in biotechnology